Ovarian Cancer

Peter Levonian, MS, senior genetic counselor, Stanford Medicine, discusses the potential risks of genetic testing in ovarian cancer.

Valerie Sugiyama, MD, discusses the treatment of patients with recurrent ovarian cancer.

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended to expand the approval of single-agent rucaparib as a maintenance therapy in adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.

The frequency of hereditary mutations that convey an increased risk of ovarian cancer suggests that many cases of the disease are preventable.

Since the introduction of platinum agents in ovarian cancer, it is reasonable to suggest there have been only limited changes in the basic paradigm of ovarian cancer management over the past several decades.

David O’Malley, MD, discusses the findings from the SOLO-1 and QUADRA studies, as well as the future of PARP inhibition in ovarian cancer.

Trung Nguyen, DO, MBA, discusses the evolving options for the treatment of patients with newly diagnosed advanced ovarian cancer.

Amer Karam, MD, discussed surgical options for patients with advanced-stage ovarian cancer and the emergence of neoadjuvant chemotherapy.

Oliver Dorigo, MD, PhD, discusses the promise of immunotherapy in ovarian cancer.

Jonathan S. Berek, MD, MMS, outlines the changing paradigm of ovarian cancer.

Elisabeth Diver, MD, discusses ongoing advances with PARP inhibitors in ovarian cancer.

Shannon N. Westin, MD, MPH, clinical investigator, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses PARP inhibitors being tested in clinical trials.